MAOB and Parkinson disease: Apart from levodopa, which is the most popular therapeutic agent for PD, several irreversible MAOB inhibitors have been widely prescribed for PD patients as an early monotherapy or an add-on to other medications, despite some reports demonstrating their discouraging clinical effects [25,26].